NGAL and NT-proBNP levels in diabetic patients with macroproteinuria

References

• Takazakura E, Nakamoto Y, Hayakawa H, Kawai K, Muramoto S. Onset and progression of diabetic glomerulosclerosis: a prospective study based on serial renal biopsies. Diabetes. 1975;24(1):1–9
   PubMed Web of Science ®Google Scholar
• Feest TG, Dunn EJ, Burton CJ. Can intensive treatment alter the progress of established diabetic nephropathy to end-stage renal failure? QJM. 1999;92(5):275–282
   PubMedGoogle Scholar
• Stern N, Tuck ML. Mechanisms of hypertension in diabetes mellitus. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. New York: Raven; 1995:2301–2314
   Google Scholar
• Feldt-Rasmussen B, Mathiesen ER, Deckert T, et al. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin--aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:610
   PubMed Web of Science ®Google Scholar
• Weidmann P. Pathogenesis of hypertension accompanying diabetes mellitus. Contrib Nephrol. 1988;73:73
   Google Scholar
• Liang F, Gardner DG. Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes. J Biol Chem. 1998;273:14612–14619
   PubMed Web of Science ®Google Scholar
• Richards AM, Crozier IG, Holmes SJ, Espiner EA, Yandle TG, Frampton C. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J Hypertens. 1993;11:163–170
   PubMed Web of Science ®Google Scholar
• Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real time indicator of active kidney damage. Kidney Int. 2007;71:967–70
   PubMed Web of Science ®Google Scholar
• Bolignano D, Donato V, Coppolino G, Campo C, Lacquaniti A, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J kidney Dis. 2008;52:595–609
   PubMed Web of Science ®Google Scholar
• Brunner HI, Mueller M, Rutherford C, et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in child-hood-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2577–2584
   PubMedGoogle Scholar
• Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337–344
   PubMed Web of Science ®Google Scholar
• Kim SS, Song SH, Kim IJ, et al. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract. 2012;97(2):251–257
   PubMed Web of Science ®Google Scholar
• Fu WJ, Li BL, Wang SB, et al. Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract. 2012;95(1):105–109
   PubMed Web of Science ®Google Scholar
• Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine. 2009;36(1):45–51
   PubMedGoogle Scholar
• Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007;9:872–878
   PubMed Web of Science ®Google Scholar
• Palazzuoli A, Beltrami M, Pellegrini M, Nuti R. Natriuretic peptides and NGAL in heart failure: does a link exist? Clin Chim Acta. 2012;413(23–24):1832–1838
   PubMedGoogle Scholar
• Klein R, Klein BE, Linton KL, Moss SE. Micro-albuminurian a population-based study of diabetes. Arch Intern Med. 1992;152:153–158
   PubMedGoogle Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–470
   PubMed Web of Science ®Google Scholar
• Spanaus KS, Kronenberg F, Ritz E, et al. Mild-to-Moderate Kidney Disease Study Group. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem. 2007;53(7):1264–1272
   PubMedGoogle Scholar
• Desai AS, Toto R, Jarolim P, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011;58(5):717–728
   PubMed Web of Science ®Google Scholar
• Locatelli F, Eckardt KU, Macdougall IC, et al. Cardiovascular risk reduction in early anaemia trial with epoetin beta investigators and coordinators. Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study. Curr Med Res Opin. 2010;26(11):2543–2552
   PubMed Web of Science ®Google Scholar
• Yasuda K, Kimura T, Sasaki K, et al. Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease. Nephrol Dial Transplant. 2012;27(10):3885–3891
   PubMedGoogle Scholar
• Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 2003;64:1772–1779
   PubMed Web of Science ®Google Scholar
• Ditzel J, Brochner-Mortensen J. Tubular reabsorption rates as related to elevated glomerular filtration in diabetic children. Diabetes. 1983;32(Suppl 2):28
   PubMed Web of Science ®Google Scholar
• Tuck ML, Corry D, Trujillo A. Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. Am J Med. 1990;88:210
   PubMed Web of Science ®Google Scholar
• McKenna K, Smith D, Moore K, Glen A, Tormey W, Thompson CJ. Brain natriuretic peptide increases urinary albumin and alpha-1 microglobulin excretion in Type 1 diabetes mellitus. Diabet Med. 2001;18:973–978
   PubMedGoogle Scholar
• Siebenhofer A, Ng LL, Plank J, Berghold A, Hödl R, Pieber TR. Plasma N-terminal pro-brain natriuretic peptide in Type 1 diabetic patients with and without diabetic nephropathy. Diabet Med. 2003;20(7):535–539
   PubMedGoogle Scholar
• Zietse R, Derkx FH, Weimar W, Schalekamp MA. Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. J Am Soc Nephr. 1995;5:2057–2066
   PubMed Web of Science ®Google Scholar
• Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int. 2011;79:1113–1118
   PubMed Web of Science ®Google Scholar